The Inhibitory Effect of Sulforaphane on The Proliferation of Acute Myeloid Leukemia Cell Lines through Controlling miR-181a.
Acute Myeloid Leukemia
Sulforaphane
miR-181a
Journal
Cell journal
ISSN: 2228-5806
Titre abrégé: Cell J
Pays: Iran
ID NLM: 101566618
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
17
03
2020
accepted:
22
07
2020
entrez:
19
2
2022
pubmed:
20
2
2022
medline:
20
2
2022
Statut:
ppublish
Résumé
The present study investigated the role of miR-181a as a small non-coding RNA molecule in acute myeloid leukemia (AML) pathogenesis and reflected on the effects of Sulforaphane (SFN) on AML progression. This experimental study had two parts. The results of this study showed an increasing trend (2.9-fold, P=0.0019) in miR-181a expression levels in AML patients as compared with HCs. The data associated with MTT assay and flow cytometry (FCM) additionally demonstrated the anti-proliferative effects of SFN against AML cell lines, with a reduction in miR-181a levels. As well, no significant difference was noted between 24 hours and 48 hours treatments by SFN. It was deduced that modulation of miR-181a expression levels could be one of the mechanisms associated with the anti-proliferative effects of SFN against AML. MiR-181a levels contribute to AML pathogenesis and thus they can be considered as a strategy in controlling AML progression in patients. Accordingly, SFN can arrest cell proliferation and induce apoptosis in AML cell lines through retardation expression of miR-181a and affecting miR-181a pathway, which already clarified its role in the differentiation of hematopoietic stem cells and indicates another mode of anti-cancer action of sulforaphane.
Identifiants
pubmed: 35182064
doi: 10.22074/cellj.2022.7508
pmc: PMC8876260
doi:
Types de publication
Journal Article
Langues
eng
Pagination
44-50Informations de copyright
Copyright© by Royan Institute. All rights reserved.
Déclaration de conflit d'intérêts
There is no conflict of interest in this study.
Références
J Cancer Res Clin Oncol. 2016 Jan;142(1):77-87
pubmed: 26113450
Curr Pharmacol Rep. 2015 Nov 1;1(6):382-390
pubmed: 26557472
Pediatr Clin North Am. 2008 Feb;55(1):21-51, ix
pubmed: 18242314
Mol Biol Rep. 2018 Dec;45(6):2491-2499
pubmed: 30350234
Gen Physiol Biophys. 2018 Mar;37(2):129-140
pubmed: 29593120
Exp Cell Res. 2013 Mar 10;319(5):697-706
pubmed: 23333498
Cancer Lett. 2017 May 28;394:52-64
pubmed: 28254410
Environ Toxicol. 2017 Jan;32(1):311-328
pubmed: 26833863
Drug Des Devel Ther. 2018 Sep 11;12:2905-2913
pubmed: 30254420
Oncotarget. 2016 Sep 13;7(37):59273-59286
pubmed: 27517749
Leukemia. 2007 May;21(5):912-6
pubmed: 17330104
Biomed Pharmacother. 2020 Jan;121:109635
pubmed: 31739165
Mol Cancer Ther. 2004 Oct;3(10):1239-48
pubmed: 15486191
Anticancer Res. 2013 Feb;33(2):445-52
pubmed: 23393335
Br J Haematol. 2020 Mar;188(6):e90-e94
pubmed: 32077100
Blood. 2013 Jan 3;121(1):159-69
pubmed: 23100311
Dev Biol. 2007 Feb 1;302(1):1-12
pubmed: 16989803
Oncotarget. 2017 Jan 10;8(2):3666-3682
pubmed: 27705921
Oncogene. 2015 Jun;34(25):3226-39
pubmed: 25174404
Oxid Med Cell Longev. 2016;2016:6719534
pubmed: 26682013
Int J Surg Protoc. 2018 Dec 24;13:1-4
pubmed: 31851750
Int J Pharm. 2019 Mar 10;558:311-318
pubmed: 30641176
Oncol Rep. 2017 May;37(5):2829-2838
pubmed: 28393231
PLoS One. 2012;7(12):e51251
pubmed: 23251470
Lancet. 2006 Nov 25;368(9550):1894-907
pubmed: 17126723
CA Cancer J Clin. 2014 Sep-Oct;64(5):311-36
pubmed: 25104502
Carcinogenesis. 2012 Oct;33(10):1833-42
pubmed: 22739026